Document |
Document Title |
WO/2023/205504A9 |
The invention provides the use of kinase inhibitors and derivatives of staurosporine, such as PKC412, to treat patients having epidermis bullosa simplex (BBS), epidermolytic hyperkeratosis, epidermolytic palmoplantar keratoderma, palmopl...
|
WO/2024/006879A1 |
Provided herein are inhibitors of ubiquitin-specific-processing Protease 1 (USP1), their pharmaceutical compositions, and methods of use for treating diseases or disorders, such as cancers described herein.
|
WO/2024/006881A1 |
Provided herein are compounds and compositions thereof that reduce WEE1 kinase protein levels. In some embodiments, the compounds and compositions are provided for treatment WEE1 associated diseases such as cancer.
|
WO/2024/006781A1 |
The application relates to bifunctional compounds of the general formula I-3' which act as degraders of the estrogen receptor alpha(ERα) and are useful for treating disorders associated with ERα-mediated transcription regulation such a...
|
WO/2024/002373A1 |
The present invention relates to a substituted pyrimidine-fused ring inhibitor, a method for preparing same, and use thereof. Specifically, the compound of the present invention has a structure represented by formula (I). Further disclos...
|
WO/2023/247666A1 |
The invention provides compounds having the general formula (I) wherein A, L, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
|
WO/2023/247670A1 |
The present invention provides compounds of formula (I) CB (I) or pharmaceutically acceptable salts thereof, wherein R3 to R5, R4a, B and C are as described herein, compositions including the compounds, processes of manufacturing the com...
|
WO/2023/245611A1 |
The present invention belongs to the field of organic synthesis medicines, and particularly relates to a small molecule compound with TTK inhibitory activity. The general formula of the small molecule compound is shown in formula (I). Th...
|
WO/2023/247590A1 |
The disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of formula (I), as well as methods of their use and preparation, are also described.
|
WO/2023/248240A1 |
The present disclosure relates to novel crystalline forms of bictegravir sodium and processes for their preparation.
|
WO/2023/033740A9 |
Compounds of the general formula (I) as described and defined herein, methods for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds and pharmaceutical compositi...
|
WO/2023/248117A2 |
The present invention relates to a temperature integrity sensor or more precisely a temperature continuity sensor of a product which needs to be kept at a temperature below its degradation temperature, such as for instance a refrigerated...
|
WO/2023/246777A1 |
The invention relates to KRAS mutant protein inhibitors of formula (I) or formula (II), a composition containing the same and the use thereof.
|
WO/2023/243686A1 |
The present invention provides a compound that exhibits a PLD-inhibitory activity. The present invention provides a compound having the following structural formula or the like, or a pharmaceutically acceptable salt thereof. (Each symb...
|
WO/2023/241137A1 |
The present application relates to the technical field of organic electroluminescent materials, and provides a nitrogen-containing compound, and an organic electroluminescent apparatus and an electronic device comprising same. The nitrog...
|
WO/2023/241136A1 |
The present application relates to the technical field of organic electroluminescent materials, and provides a heterocyclic compound, and an organic electroluminescent apparatus and an electronic device comprising same. The heterocyclic ...
|
WO/2023/240038A1 |
This disclosure provides compounds of Formula (I) (e.g., Formula (I-aa) (e.g., Formula (I-aa-1), (I-aa-2), (I-aa-3), (I-aa-4), (I-aa-5), or (I-aa-6)), Formula (I-a) (e.g., Formula (I-a-1), (I-a-2), (I-a-3), (I-a-4), (I-a-5), or (I-a-6)),...
|
WO/2023/237580A1 |
The present invention concerns new tricyclic spirolactams (TriSLas) compounds and their use as a drug, in particular for the prevention and/or treatment of a mycobacterial infection or for the treatment of a disease caused by infection w...
|
WO/2023/238065A1 |
Small molecule inhibitors of Nav1.8 voltage-gated sodium ion channel, including compounds of formula (I), (II), (III), (IV), and (V) are described. Also described are pharmaceutical compositions containing a compound of formula (I), (II)...
|
WO/2023/240263A1 |
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
|
WO/2023/232946A1 |
The present invention relates to an organic electroluminescent device comprising a compound of Formula (I), and an organic electronic device comprising the organic electroluminescent device.
|
WO/2023/232145A1 |
Disclosed in the present invention are a small molecule of homocamptothecins and the use thereof. Specifically disclosed in the present invention are a small molecule of homocamptothecins as shown in formula (I) or a pharmaceutically acc...
|
WO/2023/231777A1 |
Provided are certain BCL-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
|
WO/2023/232966A1 |
Provided herein are compounds of Formula (I), (I), or pharmaceutically acceptable salt thereof, wherein m, n, p, A1, A2, A3, A4, L, R1, R2, R3, R4, Formula (II), (II), V, X, Y and Z are defined herein. Also provided herein are pharmaceut...
|
WO/2023/232776A1 |
The present invention relates to compounds of formula (I), wherein R1 to R7, A1 and A2 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
|
WO/2023/226940A1 |
The present application relates to the technical field of medicine, and relates to a use and a pharmaceutical composition of an indolo heptamyl oxime analog, and in particular to a use of a compound of formula (I), and a pharmaceutical c...
|
WO/2023/229430A1 |
The present invention relates to a heteroaryl derivative and uses thereof. The heteroaryl derivative of the present invention exhibits excellent inhibitory activity against EGFR, and thus can be effectively used as a therapeutic agent fo...
|
WO/2023/225041A1 |
Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related disea...
|
WO/2023/223057A1 |
The invention relates to selected macrocyclic compounds, and their use in the treatment or prevention of diseases and disorders. In particular, though not exclusively, the invention relates to the use of selected macrocyclic compounds in...
|
WO/2023/222762A1 |
The present disclosure relates to proteolysis targeting chimeras (PROTACs) that modulate N6-adenosine-methyltransferase and methods of using the same.
|
WO/2023/225097A1 |
Provided are, inter alia, compounds having a structure of Formula (I)-(VL), pharmaceutical compositions including the same, and methods of use. In one aspect, compounds are provided that can inhibit salt-inducible kinases (SIK) and metho...
|
WO/2023/225302A1 |
Provided herein are aza-tetracyclic oxazepinyl compounds useful in the treatment of cancers.
|
WO/2023/224981A1 |
Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such...
|
WO/2023/222005A1 |
The present invention belongs to the technical field of medicines, and relates to a class of aromatic heterocyclic compounds serving as an LRRK2 inhibitor. The present invention provides a class of compounds with a novel structure, which...
|
WO/2023/224924A1 |
Processes and methods of preparing Compound I are disclosed. Crystalline forms of Compound I, pharmaceutically acceptable salts, solvates, hydrates, and cocrystals thereof, pharmaceutical compositions comprising the same, methods of trea...
|
WO/2023/217230A1 |
The present invention provides a KIF18A inhibitor and a method for synthesizing same. The compound of the present invention can regulate KIF18A protein to influence the cell cycle and the cell proliferation process, so as to treat cancer...
|
WO/2023/220129A1 |
The present disclosure features compounds of Formula I, Formula I, or pharmaceutically acceptable salts thereof, and formulations containing the same. Methods of treating BAF complex-related disorders, such as cancer, are also disclosed.
|
WO/2023/216871A1 |
A compound having a structure of formula (I), (IA), (II) or (IIA), or a pharmaceutically acceptable salt thereof, and an application of the compound or salt thereof in inhibiting an EGFR comprising a mutant EGFR, comprising treating canc...
|
WO/2023/218419A1 |
The present invention relates to the control of the quantity of genotoxic impurities, in particular nitrosamines, in rifampicin. In particular, the present invention relates to a process for the preparation of rifampicin substantially fr...
|
WO/2023/217045A1 |
Disclosed is a series of fluorine-substituted heterocyclic compounds, and specifically, disclosed are a compound represented by formula (XII) and a pharmaceutically acceptable salt thereof.
|
WO/2023/217201A2 |
Disclosed in the present invention is a novel pyrimido-heterocyclic compound having WEE1 target inhibitory activity, and specifically discloses a compound having a structure represented by formula (I) or a pharmaceutically acceptable sal...
|
WO/2023/220541A1 |
Tetrahydropyrido[3,4-d]pyrimidine compounds are provided that are potent HPK1 inhibitors. The compounds are useful to treat or prevent cancer and/or inflammatory and/or autoimmune diseases or symptoms thereof in mammals, particularly hum...
|
WO/2023/215220A1 |
The present disclosure provides, in part, compounds of formula (I), or a stereoisomer and/or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein; pharmaceutical compositions comprising the compounds; a...
|
WO/2023/206274A1 |
The present disclosure provides an organic electroluminescent diode and a display panel, belonging to the technical field of display. The organic electroluminescent diode comprises an anode, a luminescent layer, a hole blocking layer, an...
|
WO/2023/207710A1 |
Provided are an antibody-drug conjugate, a pharmaceutical composition thereof and use thereof. Particularly, provided are an antibody-drug conjugate of formula (I), a drug-linker for preparing the antibody-drug conjugate, and use of the ...
|
WO/2023/212240A1 |
The present disclosure relates generally to inhibitors of KIF18A, compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to inhibitors of KIF18A and methods o...
|
WO/2023/210741A1 |
The present invention addresses the problem of providing a medicine capable of treating and/or preventing a disease associated with oxidative stress through the inhibition of a protein-protein interaction between Keap1 and Nrf2 to activa...
|
WO/2023/208124A1 |
The present application relates to a substituted piperidine carboxamide azaindane derivative, a method for preparing same, and use of a pharmaceutical composition containing the derivative or a deuterated derivative in medicine. Specific...
|
WO/2023/210623A1 |
The present invention is a novel haloalkyl sulfone anilide compound or a salt thereof, an herbicide composition including said compound or salt thereof, an herbicide method including a step for applying the herbicide composition, and a m...
|
WO/2023/210740A1 |
The present invention addresses the problem of providing a medicinal drug that can treat and/or prevent diseases linked to oxidative stress, by inhibiting the protein-protein interaction between Keap1 and Nrf2 to activate Nrf2. The prese...
|